D.A. Davidson & CO. Invests $713,000 in Kenvue Inc. (NYSE:KVUE)

D.A. Davidson & CO. bought a new position in shares of Kenvue Inc. (NYSE:KVUEFree Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 35,497 shares of the company’s stock, valued at approximately $713,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kistler Tiffany Companies LLC purchased a new position in Kenvue in the second quarter worth $26,000. Tamarack Advisers LP purchased a new position in Kenvue in the second quarter worth $26,000. Arete Wealth Advisors LLC boosted its position in Kenvue by 5.7% in the third quarter. Arete Wealth Advisors LLC now owns 18,835 shares of the company’s stock worth $378,000 after purchasing an additional 1,016 shares during the last quarter. Clearstead Advisors LLC purchased a new position in Kenvue in the third quarter worth $25,000. Finally, EverSource Wealth Advisors LLC bought a new stake in shares of Kenvue in the third quarter valued at $28,000. Hedge funds and other institutional investors own 11.33% of the company’s stock.

Kenvue Stock Up 1.4 %

Kenvue stock opened at $19.60 on Tuesday. Kenvue Inc. has a 52 week low of $17.82 and a 52 week high of $27.80. The business has a 50-day simple moving average of $20.94 and a 200 day simple moving average of $21.00. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.78 and a current ratio of 1.14.

Kenvue (NYSE:KVUEGet Free Report) last posted its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 14.83% and a net margin of 9.87%. The business had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. The firm’s revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts predict that Kenvue Inc. will post 1.19 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.08%. The ex-dividend date is Tuesday, February 13th.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KVUE shares. Piper Sandler started coverage on Kenvue in a research note on Friday, November 17th. They issued a “neutral” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday. UBS Group boosted their target price on Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, December 19th. Finally, Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.92.

Check Out Our Latest Research Report on Kenvue

About Kenvue

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.

See Also

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.